Dr. Ningshu Liu brings over 25 years of leadership and R&D experience in targeted oncology and immuno-oncology, spanning roles at both multinational and domestic pharmaceutical companies.
Prior to joining Asieris, she served as Co-Chief Scientific Officer at Fosun Pharma’s Global R&D Center，Chairman of FosunPharma S-Infinity, and Senior Vice President of Translational Medicine at Henlius.
Previously, Dr. Liu spent over 20 years at Bayer, where she held positions including Sr. Director-Global Strategy Lead, Head of Laboratory Immuno-Oncology, Head of Laboratory Oncogenic Signaling in Bayer Germany, Group leader of Oncology Research in Bayer Research Center USA, Group Manager of Asthma and Inflammation diseases in Bayer Research Center Kyoto, etc.
During her tenure at Bayer, Dr. Liu led multiple major R&D programs, advancing several innovative therapies into clinical development. Notably, as program lead, she guided the PI3K inhibitor Copanlisib from early discovery through clinical development to eventual approval by the U.S. Food and Drug Administration (FDA).
Dr. Ningshu Liu holds a Bachelor of Science degree in Physiology and Biophysics from Peking University, a Master of Science degree in Biochemistry and Molecular Biology from Tokyo University, and a Ph.D. in Human Medicine from the University of Marburg.
